Download PDF
CC BY 4.0 · European Journal of General Dentistry
DOI: 10.1055/s-0043-1777841
Original Article

Identification of Repurposed FDA Drugs by Targeting Sclerostin via the Wnt Pathway for Alveolar Bone Formation

Pradeep K. Yadalam
1   Department of Periodontics, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences , Saveetha University, Chennai, Tamil Nadu, India
,
Raghavendra V. Anegundi
1   Department of Periodontics, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences , Saveetha University, Chennai, Tamil Nadu, India
,
Ramya Ramadoss
2   Department of Oral Pathology and Oral Biology, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India
,
Deepti Shrivastava 
3   Periodontics Division, Preventive Dentistry Department, College of Dentistry, Jouf University, Sakaka, Saudi Arabia
,
Awsaf Murdhi Alruwaili
4   College of Dentistry, Jouf University, Sakaka, Saudi Arabia
,
Muhammad Faheemuddin 
5   Department of Prosthodontics and Implantology, College of Dentistry, King Faisal University, Al-Ahsa, Saudi Arabia
,
Kumar Chandan Srivastava 
6   Oral Medicine and Maxillofacial Radiology Division, Department of Oral and Maxillofacial Surgery and Diagnostic Sciences, College of Dentistry, Jouf University, Sakaka, Saudi Arabia
7   Department of Oral Medicine and Radiology, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, India
› Author Affiliations
› Further Information
   Permissions and Reprints


Abstract

Objective Natural wingless-related integration site (Wnt) pathway antagonist sclerostin (SOST) has attracted much attention because unusual bone illnesses characterized by the increased bone mass result from its absence of action. The Wnt ligand is prevented from attaching to the Frizzled family receptor when SOST is present. In the active destruction complex, -catenin is phosphorylated. -Catenin molecules do not enter the nucleus and are broken down by a proteasome. As a result, Wnt-responsive genes are not activated, which lowers bone formation and raises bone resorption. A humanized monoclonal antibody called romosozumab binds to and inhibits SOST with significant cardiac side effects. As a result, the current study's objective is to find and screen Food and Drug Administration (FDA) medications that target SOST.

Materials and Methods SOST's structure was retrieved from Protein Data Bank (PDB) (ID: 6l6r). Pharmacophore modeling and molecular operating environment-based virtual testing of FDA-approved medicines. Using the Desmond program, docking and molecular dynamics simulations were performed.

Results Our findings revealed medications with FDA approval (ZINC000253387843) Amphotericin B. The stability and receptor–ligand interactions are pretty substantial, as demonstrated by the findings of docking and Molecular dynamics simulations, which have a docking score of −7.3 k/mol and root mean square deviation stability at 40 nanoseconds, respectively.

Conclusion The suggested pharmacological therapy shows promise since it uses the Wnt pathway to target the primary bone formation mechanism. However, additional prospective studies are required to apply the available data to clinical practice.

Keywords

bone remodeling - sclerostin - periodontal disease - Wnt pathway - osteoblast


Publication History

Article published online:
26 March 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Brent MB, Brüel A, Thomsen JS. Anti-sclerostin antibodies and abaloparatide have additive effects when used as a countermeasure against disuse osteopenia in female rats. Bone 2022; 160: 116417
    CrossrefPubMedGoogle Scholar
  • 2 Ramli FF, Chin K-Y. A review of the potential application of osteocyte-related biomarkers, fibroblast growth factor-23, sclerostin, and Dickkopf-1 in predicting osteoporosis and fractures. Diagnostics (Basel) 2020; 10 (03) 145
    CrossrefPubMedGoogle Scholar
  • 3 Balemans W, Van Den Ende J, Freire Paes-Alves A. et al. Localization of the gene for sclerosteosis to the Van Buchem disease-gene region on chromosome 17q12-q21. Am J Hum Genet 1999; 64 (06) 1661-1669
    CrossrefPubMedGoogle Scholar
  • 4 Hu B, Li Y, Wang M. et al. Functional reconstruction of critical-sized load-bearing bone defects using a Sclerostin-targeting miR-210-3p-based construct to enhance osteogenic activity. Acta Biomater 2018; 76: 275-282
    CrossrefPubMedGoogle Scholar
  • 5 Van Hul W, Balemans W, Van Hul E. et al. Van Buchem disease (hyperostosis corticalis generalisata) maps to chromosome 17q12-q21. Am J Hum Genet 1998; 62 (02) 391-399
    CrossrefPubMedGoogle Scholar
  • 6 Yu S, Li D, Zhang N. et al. Drug discovery of sclerostin inhibitors. Acta Pharm Sin B 2022; 12 (05) 2150-2170
    CrossrefPubMedGoogle Scholar
  • 7 Yan Y, Tang D, Chen M. et al. Axin2 controls bone remodeling through the β-catenin-BMP signaling pathway in adult mice. J Cell Sci 2009; 122 (Pt 19): 3566-3578
    CrossrefPubMedGoogle Scholar
  • 8 Ke HZ, Richards WG, Li X, Ominsky MS. Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. Endocr Rev 2012; 33 (05) 747-783
    CrossrefPubMedGoogle Scholar
  • 9 Witcher PC, Miner SE, Horan DJ. et al. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition. JCI Insight 2018; 3 (11) e98673
    CrossrefPubMedGoogle Scholar
  • 10 Sutherland MK, Geoghegan JC, Yu C. et al. Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone 2004; 35 (04) 828-835
    CrossrefPubMedGoogle Scholar
  • 11 Shu R, Bai D, Sheu T. et al. Sclerostin promotes bone remodeling in the process of tooth movement. PLoS ONE 2017; 12 (01) e0167312
    CrossrefPubMedGoogle Scholar
  • 12 Li X, Ominsky MS, Niu QT. et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008; 23 (06) 860-869
    CrossrefPubMedGoogle Scholar
  • 13 Qi J, Liu E, Guo Y-F. et al. Association between periodontal disease and osteoporosis in postmenopausal women: a protocol for systematic review and meta-analysis. BMJ Open 2021; 11 (09) e049277
    CrossrefPubMedGoogle Scholar
  • 14 Hong S-J, Yang B-E, Yoo D-M, Kim S-J, Choi H-G, Byun S-H. Analysis of the relationship between periodontitis and osteoporosis/fractures: a cross-sectional study. BMC Oral Health 2021; 21 (01) 125
    CrossrefPubMedGoogle Scholar
  • 15 Esfahanian V, Shamami MS, Shamami MS. Relationship between osteoporosis and periodontal disease: review of the literature. J Dent (Tehran) 2012; 9 (04) 256-264
    Google Scholar
  • 16 Martínez-Maestre MÁ, González-Cejudo C, Machuca G, Torrejón R, Castelo-Branco C. Periodontitis and osteoporosis: a systematic review. Climacteric 2010; 13 (06) 523-529
    CrossrefPubMedGoogle Scholar
  • 17 Liao C, Ou Y, Wu Y, Zhou Y, Liang S, Wang Y. Sclerostin inhibits odontogenic differentiation of human pulp-derived odontoblast-like cells under mechanical stress. J Cell Physiol 2019; 234 (11) 20779-20789
    CrossrefPubMedGoogle Scholar
  • 18 Liu M, Kurimoto P, Zhang J. et al. Sclerostin and DKK1 inhibition preserves and augments alveolar bone volume and architecture in rats with alveolar bone loss. J Dent Res 2018; 97 (09) 1031-1038
    CrossrefPubMedGoogle Scholar
  • 19 Yao Y, Kauffmann F, Maekawa S. et al. Sclerostin antibody stimulates periodontal regeneration in large alveolar bone defects. Sci Rep 2020; 10 (01) 16217
    CrossrefPubMedGoogle Scholar
  • 20 Brown JP, Prince RL, Deal C. et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009; 24 (01) 153-161
    CrossrefPubMedGoogle Scholar
  • 21 Lv F, Cai X, Yang W. et al. Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis. Bone 2020; 130: 115121
    CrossrefPubMedGoogle Scholar
  • 22 Saag KG, Petersen J, Brandi ML. et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 2017; 377 (15) 1417-1427
    CrossrefPubMedGoogle Scholar
  • 23 Minisola S. Romosozumab: from basic to clinical aspects. Expert Opin Biol Ther 2014; 14 (09) 1225-1228
    CrossrefPubMedGoogle Scholar
  • 24 Cosman F, Crittenden DB, Adachi JD. et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 2016; 375 (16) 1532-1543
    CrossrefPubMedGoogle Scholar
  • 25 Sahoo BM, Ravi Kumar BVV, Sruti J, Mahapatra MK, Banik BK, Borah P. Drug repurposing strategy (DRS): emerging approach to identify potential therapeutics for treatment of novel coronavirus infection. Front Mol Biosci 2021; 8: 628144
    CrossrefPubMedGoogle Scholar
  • 26 Ferreira LG, Dos Santos RN, Oliva G, Andricopulo AD. Molecular docking and structure-based drug design strategies. Molecules 2015; 20 (07) 13384-13421
    CrossrefPubMedGoogle Scholar
  • 27 Rasheed MA, Iqbal MN, Saddick S. et al. Identification of lead compounds against Scm (fms10) in Enterococcus faecium using computer aided drug designing. Life (Basel) 2021; 11 (02) 77
    Google Scholar
  • 28 Hildebrand PW, Rose AS, Tiemann JKS. Bringing molecular dynamics simulation data into view. Trends Biochem Sci 2019; 44 (11) 902-913
    CrossrefPubMedGoogle Scholar
  • 29 Salo-Ahen OM, Alanko I, Bhadane R. et al. Molecular dynamics simulations in drug discovery and pharmaceutical development. Processes (Basel) 2020; 9 (01) 71
    CrossrefGoogle Scholar
  • 30 Muthusamy K, Mohan S, Nagamani S, Kesavan C. Identification of novel small molecules that bind to the loop2 region of sclerostin - an in silico computational analysis. Physiol Res 2016; 65 (05) 871-878
    CrossrefPubMedGoogle Scholar
  • 31 Yooin W, Saenjum C, Ruangsuriya J, Jiranusornkul S. Discovery of potential sclerostin inhibitors from plants with loop2 region of sclerostin inhibition by interacting with residues outside Pro-Asn-Ala-Ile-Gly motif. J Biomol Struct Dyn 2020; 38 (05) 1272-1282
    CrossrefPubMedGoogle Scholar
  • 32 Choi J, Lee K, Kang M, Lim S-K, Tai No K. In silico discovery of quinoxaline derivatives as novel LRP5/6-sclerostin interaction inhibitors. Bioorg Med Chem Lett 2018; 28 (06) 1116-1121
    CrossrefPubMedGoogle Scholar
  • 33 Chandra A, Rajawat J. Skeletal aging and osteoporosis: mechanisms and therapeutics. Int J Mol Sci 2021; 22 (07) 3553
    CrossrefPubMedGoogle Scholar